Omalizumab in Refractory Adult-Onset Facial Atopic Dermatitis: A Case Report

Purpose

Adult-onset facial atopic dermatitis (AFAD) is a distinct subtype of atopic dermatitis that predominantly affects the face and is frequently misdiagnosed as rosacea or other facial dermatoses. The management of AFAD is challenging, particularly in patients who respond poorly to conventional therapies. At present, reports on the use of anti-immunoglobulin E (IgE) therapy in AFAD are limited. Herein, we report a case of AFAD with markedly elevated serum IgE levels that showed a favorable response to omalizumab. Patients and Methods: A retrospective analysis was conducted on the clinical characteristics, laboratory findings, treatment course, and therapeutic outcomes of a patient with AFAD. Pruritus severity was assessed using a visual analog scale (VAS, 0– 10). Facial erythema and skin dryness were evaluated using the objective sign components of the SCORAD index. Clinical photographs and objective assessment results were recorded during follow-up.